Electronic literature searches were conducted in PubMed/MEDLINE, Scopus, and Web of Science from database inception through January 2026. To maximize search sensitivity, the strategy combined controlled vocabulary with free-text keywords and Boolean operators across three primary domains:

Additionally, the reference lists of all eligible articles and relevant seminal reviews were manually screened to capture supplemental studies not identified in the primary database query.

Eligibility criteria were defined a priori. To be included in the primary synthesis, studies were required to be peer-reviewed, English-language original research articles that met at least one of the following scientific criteria:

Studies were excluded if they were conference abstracts lacking full text, editorials, commentaries, or non-English publications. To ensure the review captured the most current and highly relevant mechanistic data, preprints were universally eligible for inclusion provided they strictly met the predefined PCC criteria. However, because preprints have not yet undergone formal peer review, their findings were interpreted with appropriate methodological caution. Finally, studies were excluded if they lacked interpretable experimental controls, utilized poorly validated models preventing meaningful mechanistic interpretation, or did not clearly relate to CNS α₂A-AR biology.

Following the removal of duplicate records, citations were screened by title and abstract, followed by a full-text review against the eligibility criteria. For each included source, data were charted regarding the study type, experimental model (species/tissue preparation), epileptogenic trigger, pharmacological intervention, comparator condition, and principal mechanistic findings. Particular analytical focus was placed on variables likely to influence pharmacological interpretation, such as the receptor subtype interrogated and whether the observed drug effects reflected global network suppression versus state-dependent modulation of pathological activity.

Due to the substantial heterogeneity in model systems, experimental designs, and endpoints across the selected literature, the evidence was synthesized narratively rather than via meta-analysis. In alignment with standard scoping review methodology, a formal quantitative risk-of-bias tool was not applied 21,22. However, the methodological rigor of the included studies—specifically model validity, pharmacological specificity, and the use of appropriate controls—was assessed qualitatively throughout the synthesis to ensure robust evidence mapping (Figure 1).

The selection process and the number of records identified, screened, and included are detailed in the PRISMA-ScR flow diagram (Figure 2). Furthermore, the characteristics, models, and principal findings of the included preclinical studies are charted in Table 1 to support the data extraction process.

The adrenergic system is a central regulator of cardiovascular function, metabolism, and arousal 23. Its primary agonists are the catecholamines norepinephrine (NE) and epinephrine, synthesized sequentially from tyrosine in adrenal chromaffin cells and noradrenergic neurons 24. While epinephrine acts primarily as a circulating hormone, NE serves as the principal neurotransmitter in the brain 6. Noradrenergic neurons, located primarily in the locus coeruleus, project widely to the cortex, hippocampus, and amygdala. Following release, NE is cleared via reuptake and metabolism, a process that tightly regulates noradrenergic tone.

Adrenergic receptors are G protein-coupled receptors (GPCRs) classified into α1, α2, and β families 25. Functionally, these receptors diverge significantly: α1 receptors couple to Gq/11 to increase excitability, whereas β receptors couple to Gs to stimulate cAMP production 26. In contrast, the α2 family (α₂A, α2B, α2C) couples to Gi/o proteins to exert inhibitory effects 11.

The α₂A-AR is the predominant subtype in the CNS 27. Mechanistically, agonist binding inhibits adenylyl cyclase via Gαi/o, reducing cAMP/PKA activity. Concurrently, Gβγ subunits inhibit voltage-gated Ca2⁺ channels (VGCCs) and activate G-protein-gated inwardly rectifying K⁺ (GIRK) channels 28,29. Through these combined actions, α₂A-AR activation hyperpolarizes neurons and suppresses neurotransmitter release. Recent structural studies have identified key residues for ligand binding, facilitating the design of biased ligands that may optimize these signaling pathways 12.

Immunohistochemical studies reveal a strategic distribution of α₂A-ARs in seizure-relevant circuits 30. In the brainstem, they function as autoreceptors on the locus coeruleus to regulate NE firing 29. In the forebrain, specifically the hippocampus and neocortex, they are located on presynaptic terminals of Schaffer collaterals and inhibitory interneurons 31. Ultrastructural analysis confirms their localization on presynaptic boutons, supporting their role in gating excitatory transmission 31.

The molecular identification of different adrenoceptor subtypes spurred research into subtype-selective agents to improve therapeutic effectiveness and reduce off-target effects. Gene targeting studies show that the α₂A adrenoceptor subtype is responsible for many of the classical pharmacological effects linked to non-selective α₂ agonists like clonidine 32. In transgenic mouse models, activating α₂A-adrenoceptors has been associated with hypotension and bradycardia. These responses are diminished or absent when α₂A receptors are genetically disrupted, setting them apart from other α₂ subtypes 32. Additionally, α₂A adrenoceptors play a role in sedation and the central nervous system depressant effects caused by α₂ agonists 32. Neuronal α₂A receptors in the prefrontal cortex are linked to enhanced working memory and cognitive control after selective α₂A activation in primate models 33,34. Although α₂ agonists like clonidine and dexmedetomidine have pain-relieving properties, the involvement of various receptor subtypes and neural pathways makes it difficult to attribute these effects solely to α₂A-adrenoceptors 35.

Presynaptically, α₂A-ARs act as "brakes" on synaptic transmission 36. As autoreceptors, they inhibit NE release via negative feedback. As heteroreceptors on glutamatergic terminals, they significantly reduce excitatory postsynaptic potentials (EPSPs) by suppressing presynaptic Ca2+ entry 36. Crucially, this inhibition is more pronounced at excitatory synapses than GABAergic synapses, allowing for a net reduction in network excitability 36. Postsynaptically, α₂A-AR activation opens GIRK channels, generating an outward K+ current that hyperpolarizes pyramidal neurons and dampens their response to depolarizing inputs 37. Collectively, these receptors act as dynamic gain controllers (Figure 3), regulating the transformation of synaptic inputs into spiking output 38.

Seizures arise when the balance between glutamate-mediated excitation and GABA-mediated inhibition is disrupted 39,40. Under physiological conditions, glutamate activates N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors to drive depolarization, while GABA activates GABA_A and GABA_B receptors to hyperpolarize neurons 41. In epilepsy, this homeostasis is lost; reduced GABAergic inhibition or excessive glutamatergic drive leads to runaway excitation and excitotoxicity 42. While current ASMs target these systems directly, their broad modulation often results in cognitive side effects, necessitating more selective neuromodulatory approaches 43.

The noradrenergic system intersects with these primary signaling pathways to modulate seizure susceptibility 44. Evidence indicates that NE generally exerts anticonvulsant effects; NE-deficient mice exhibit increased seizure susceptibility, which is reversed by restoring NE synthesis 7,44. However, the effect is receptor-dependent: α1 activation can be proconvulsant during stress, and β activation may facilitate excitability 45. Conversely, α₂A-AR activation consistently suppresses glutamate release and inhibits epileptiform activity 9. This receptor-specific dichotomy suggests that selective α₂A targeting can harness the anticonvulsant potential of NE while avoiding the proconvulsant actions of other adrenergic subtypes 8,45.

Brimonidine (UK-14,304) was synthesized as an α2-adrenoceptor-selective imidazoline agonist with reduced lipophilicity compared to clonidine, theoretically to minimize blood-brain barrier (BBB) penetration and consequent sedation 46. However, experimental and clinical data indicate that brimonidine retains pharmacologically significant central nervous system (CNS) access. In pediatric patients, topical ophthalmic administration has precipitated lethargy, unresponsiveness, apnea, bradycardia, and hypotension, confirming its central activity 47,48. Furthermore, animal models demonstrate that radiolabeled brimonidine reaches the optic nerves, optic tracts, and olfactory bulb following ocular dosing, despite negligible systemic blood concentrations. BBB-permeation studies further corroborate brimonidine's measurable capacity to cross into the CNS 49,50. Therefore, brimonidine should be viewed as a ligand with limited but defined brain penetrance, rather than a compound entirely excluded from the CNS.

Importantly, merely increasing BBB penetration would not improve the drug's therapeutic index due to the complex autonomic biology of α2-adrenoceptors. Gene-targeting studies reveal that brainstem α₂A-receptors mediate the canonical hypotensive response, whereas peripheral α2B-receptors in vascular smooth muscle mediate vasoconstriction, which can counteract central hypotension 51,52. Reflecting this mixed cardiovascular profile, even unilateral topical brimonidine elicits measurable reductions in systemic blood pressure and heart rate in adults 53. This highlights the potent peripheral and systemic effects of the drug, which parallel its established clinical utility in lowering intraocular pressure via specific receptor cascades (Figure 4). Therefore, optimizing this drug class requires achieving CNS target engagement while minimizing both central sympatholysis and peripheral vascular receptor occupancy.

Consequently, future brimonidine-inspired ligands must be optimized across receptor subtype, signaling bias, and pharmacokinetic exposure dimensions. First, candidate molecules should exhibit selectivity for the α₂A-subtype over α2B in both binding affinity and intrinsic efficacy. Brimonidine's functional α2-selectivity is driven largely by this efficacy differential rather than an absolute affinity gap. Second, next-generation ligands must circumvent the broad, high-efficacy signaling profile of canonical imidazoline agonists. Brimonidine and dexmedetomidine function as robust agonists for both G protein activation and β-arrestin-2 recruitment at the human α₂A-receptor. Conversely, recently developed structure-guided α₂A-agonists exhibit preferential Gi/o signaling with negligible β-arrestin recruitment, preserving in vivo analgesia without inducing sedation 53. While it remains to be definitively proven that biased signaling eliminates hypotension, this establishes a clear medicinal chemistry directive: preserve orthosteric interactions required for α₂A activation while avoiding conformations linked to broad transducer engagement. Recent cryo-electron microscopy (cryo-EM) structures of the α₂A-receptor offer a template for this targeted design, highlighting conserved binding-pocket residues such as D128^3.32, Y431^7.43, and F427^7.39 54.

Third, pharmacokinetic optimization must prioritize unbound brain exposure over crude lipophilicity. In CNS drug discovery, the unbound brain-to-plasma partition coefficient is a superior metric to nominal BBB permeability, as it accounts for the net effects of influx, efflux, and non-specific tissue binding 55. An optimal brimonidine successor requires sufficient unbound CNS exposure to engage α₂A-dependent neuroprotective or spinal circuits, alongside low unbound plasma concentrations to limit systemic α2-receptor occupancy 56. Furthermore, emerging research suggests that mitigating cardiovascular liability may require circuit-level modulation rather than exclusively intensifying α₂A agonism. For instance, ADRIANA, a recently identified α2B-selective antagonist, elevates spinal noradrenaline and induces α₂A-dependent analgesia without cardiovascular side effects in murine and non-human primate models 57. This underscores a critical design principle: future CNS-active therapeutics must integrate robust brain exposure with α₂A-selective efficacy and peripheral α2B sparing, rather than pursuing global α2-adrenoceptor agonism.

Beyond its ocular effects, brimonidine exhibits neuroprotective properties 58. In optic nerve injury models, it promotes neuronal survival via ERK1/2 signaling and suppression of inflammatory pathways 59. In the context of epilepsy, the drug's ability to penetrate neural tissue and robustly activate Gi/o signaling makes it an attractive candidate for suppressing pathological excitation 60.

Ex vivo hippocampal slice studies confirm the anticonvulsant properties of brimonidine, but understanding its true mechanism requires comparing distinct epileptogenic models. In early CA3 models, epileptiform bursting was induced by pharmacologically impairing GABAergic inhibition. Under these disinhibited conditions, α₂A-adrenergic receptor (α₂A-AR) activation successfully reduced spontaneous burst frequency. This demonstrates that α₂A-ARs can suppress hyperexcitability directly by attenuating the recurrent excitatory CA3 network, rather than merely restoring lost GABAergic tone 9,38. However, the pharmacological landscape shifts significantly when epileptiform activity is induced by 4-aminopyridine (4-AP). Unlike standard disinhibition models, 4-AP blocks voltage-gated potassium channels, which broadly enhances neurotransmitter release from both excitatory and inhibitory terminals. Consequently, the 4-AP model preserves and actively recruits GABAergic signaling into the epileptiform pattern. In hippocampal slices, 4-AP generates complex synchronous activity, ranging from fast CA3-driven glutamatergic interictal events to slower GABA-dependent discharges 61. Evaluating a drug in this environment tests its efficacy in a circuit where excitation, inhibition, and propagation dynamics remain intact and highly complex.

This model-specific context clarifies recent findings regarding brimonidine's efficacy. In adult mouse hippocampal slices treated with 4-AP, brimonidine significantly increased the interval between interictal-like discharges while leaving physiological synaptic responses largely unchanged 62. This targeted response reflects state-dependent modulation. In the older CA3 model, α₂A-AR signaling is tested against a simplified substrate where recurrent excitation dominates. In the 4-AP model, the same receptor system is tested in a mechanistically mixed epileptiform state, where preserved inhibitory signaling reshapes the drug's apparent effect. Ultimately, comparing these ex vivo studies indicates that brimonidine is not acting as a uniform central nervous system depressant. Its efficacy heavily depends on the pathological state of the network. When challenged by the robust, mixed-synaptic hyperactivity of the 4-AP model, α₂A-AR agonism preferentially dampens pathological network synchronization while sparing baseline physiological transmission 9,61,62. This state-dependency provides a vital theoretical framework for how α₂A-agonists might control focal seizures without indiscriminately suppressing normal hippocampal function.

Beyond seizure suppression, the noradrenergic system is critical for preventing Sudden Unexpected Death in Epilepsy (SUDEP) 63. In DBA/1 mice, a well-established model of SUDEP, deficiencies in norepinephrine synthesis correlate with seizure-induced respiratory arrest 63. Pharmacological interventions that enhance noradrenergic tone or activate α2-adrenergic receptors have been shown to reduce the incidence of respiratory arrest significantly 14. While clonidine, a non-selective α2 agonist, was utilized in these studies, the high density of α₂A receptors in brainstem respiratory centers suggests this subtype may play a predominant role in maintaining respiratory drive during ictal events 14. Thus, α2-adrenergic modulation offers a potential dual therapeutic benefit: mitigating cortical hyperexcitability and preventing fatal cardiorespiratory collapse.

To circumvent the systemic side effects of α2 agonists (e.g., hypotension), novel delivery systems are under investigation 13. Approaches such as electrophoretic drug delivery allow for focal, on-demand administration of ASMs directly to the epileptogenic zone 13. Applying such technologies to brimonidine could maximize local antiseizure efficacy while minimizing peripheral exposure (Proctor et al., 2018).

Leveraging structural biology to design "biased" agonists that favor G-protein anticonvulsant pathways over β-arrestin pathways linked to sedation 12. Recent advances in G protein-coupled receptor (GPCR) structural biology have fundamentally transformed the approach to targeting the α₂A-adrenergic receptor. Traditional agonists, such as clonidine and brimonidine, act as "balanced" ligands; they uniformly recruit both Gi/o protein signaling pathways (which mediate the desired presynaptic anticonvulsant effects) and β-arrestin-2 pathways (which are heavily implicated in dose-limiting adverse events, such as profound sedation and cardiovascular depression). The proposal that future therapeutic success lies in "biased" agonism is rooted in the pharmacological ability to decouple these distinct intracellular cascades. Current evidence indicates that α₂A-adrenoceptor activation is the subtype most directly linked to anticonvulsant effects, as α₂A signaling suppresses epileptiform activity and contributes to endogenous seizure restraint 9,64,65. However, effective seizure control does not require indiscriminate activation of all downstream pathways. Studies in mice show that sedative responses to α2 agonists are influenced by arrestin-associated signaling machinery, whereas partial α₂A activation can preserve selected physiological effects without proportionate sedation 66,67.

By leveraging high-resolution cryo-electron microscopy (cryo-EM) structures of the human α₂A-receptor in its active state, drug discovery has moved from empirical screening to rational, structure-guided design (Xu et al., 2022). For example, recent large-scale computational docking campaigns have successfully identified novel, non-imidazoline α₂A-agonists that exhibit profound signaling bias. These molecules preferentially trigger Gi/o signaling with virtually undetectable β-arrestin recruitment 68.

At the molecular level, this functional selectivity is achieved by engineering ligands that selectively interact with specific conserved residues within the orthosteric binding pocket—most notably D128^3.32, Y431^7.43, and F427^7.39 12,68. By finely tuning the steric and electrostatic contacts with these specific amino acids, medicinal chemists can stabilize a distinct receptor conformation. This precise conformation permits the intracellular loops to engage G proteins but sterically hinders the intracellular structural rearrangements required for β-arrestin coupling. In preclinical in vivo models, these structure-derived biased ligands successfully preserved centrally mediated analgesia without inducing sedation 68. Applying this structural paradigm to epilepsy represents a highly promising translational frontier. Engineering biased α₂A-agonists could theoretically isolate the state-dependent suppression of epileptiform discharges from the systemic sympatholytic and sedative burdens that have historically precluded the chronic systemic use of these drugs in clinical neurology.

Utilizing intracranial catheters or implantable devices to deliver α₂A agonists specifically to seizure foci, beneficial for drug-resistant focal epilepsies 13. Systemic administration of α₂A-agonists is heavily restricted by dose-limiting peripheral cardiovascular effects and generalized sedation. To circumvent these translational barriers, future strategies must leverage focal delivery systems to treat drug-resistant focal epilepsies. This approach utilizes intracranial catheters or implantable micro-infusion pumps to deliver α₂A-agonists directly into the precisely mapped epileptogenic zone. By bypassing the blood-brain barrier and systemic circulation, focal delivery achieves high, sustained therapeutic drug concentrations exactly where pathological hypersynchrony originates 69. Furthermore, advancing these implantable devices could allow for integration with responsive neurostimulation (RNS) technology, creating a closed-loop system that triggers micro-infusions of the drug only upon the detection of pre-seizure electrophysiological biomarkers 70. Ultimately, restricting α₂A-AR activation exclusively to the seizure focus maximizes the local anticonvulsant efficacy while entirely eliminating the peripheral sympatholytic and broad cognitive side effects that have historically limited this drug class.

Employing low-dose α₂A agonists alongside standard ASMs to enhance seizure control and reduce SUDEP risk without compounding side effects 14. Monotherapy with standard antiseizure medications (ASMs) frequently fails to achieve complete seizure freedom or requires high doses that cause intolerable cognitive impairment. Employing low-dose α₂A-agonists as an adjunctive therapy offers a highly synergistic pharmacological approach. Because standard ASMs predominantly target postsynaptic ion channels or GABAergic pathways, the addition of a presynaptic α₂A-agonist provides a complementary mechanism to further attenuate pathological glutamate release. Importantly, utilizing this drug class at a low dose enhances seizure control while avoiding the profound sedation and hypotension that typically preclude high-dose α2-agonist monotherapy. Furthermore, this adjunctive strategy may actively mitigate the risk of Sudden Unexpected Death in Epilepsy (SUDEP). SUDEP is fundamentally driven by massive, seizure-induced autonomic dysregulation, including severe post-ictal sympathetic storms and fatal cardiac arrhythmias 71. Because α₂A-receptors function as central sympatholytics, their targeted activation can dampen these catastrophic neurocardiac reflexes, potentially offering a dual-action therapy that reduces both seizure frequency and the likelihood of fatal autonomic collapse 72.

Investigating whether the neuroprotective pathways activated by UK14,304 can retard epileptogenesis or prevent network reorganization 58. Current antiseizure medications are overwhelmingly symptomatic; they suppress seizures but do not alter the underlying pathological progression of the disease. A critical frontier in epilepsy research is determining whether the neuroprotective properties of α₂A-agonists, such as brimonidine, can offer true disease modification. Epileptogenesis—the process by which a normal brain develops chronic epilepsy following an initial insult like status epilepticus or trauma—is fundamentally driven by acute glutamate excitotoxicity, neuroinflammation, and subsequent aberrant network reorganization, including mossy fiber sprouting and neuronal death 73. Because α₂A-agonists potently inhibit presynaptic glutamate release, they directly mitigate the primary driver of excitotoxic cell damage. Furthermore, preclinical studies across various neurodegeneration and brain injury models demonstrate that α2-adrenoceptor activation upregulates neurotrophic factors and activates anti-apoptotic cellular cascades 74,75. By combining this robust anti-excitotoxic action with direct cellular neuroprotection, future translational research must investigate whether early intervention with α₂A-agonists can successfully arrest epileptogenesis and prevent pathological network rewiring, ultimately altering the natural history of the disease rather than merely masking its symptoms.

Bridging the translational gap between rodent ex vivo models and human focal epilepsy requires rigorous, proof-of-concept clinical trial designs. Currently, clinical evidence for α₂A-mediated neuroprotection or seizure suppression in the human central nervous system remains limited and inconclusive 18,19. To overcome this barrier, future early-phase trials must integrate robust, quantifiable biomarkers rather than relying solely on patient-reported seizure diaries. Non-invasive tools, such as high-density electroencephalography (hdEEG), should be utilized to quantify targeted reductions in interictal epileptiform discharges following acute drug administration. Furthermore, neuroimaging techniques like receptor-specific positron emission tomography (PET) can be deployed to confirm central target engagement and verify that the drug reaches the necessary brain structures at therapeutic concentrations.

In addition to non-invasive biomarkers, translational neurology must leverage specialized clinical environments. "Window of opportunity" (or Phase 0) trials in the epilepsy monitoring unit represent an ideal framework for testing novel α₂A-agonists 76. In these studies, patients with drug-resistant focal epilepsy who are undergoing invasive intracranial EEG (iEEG) monitoring are evaluated to assess the acute effects of the drug. This setup allows clinicians to directly and precisely measure the drug's local efficacy in suppressing pathological bursting within the exact human epileptogenic zone, overcoming the well-documented limitations and inaccuracies of patient-reported seizure diaries 77. Additionally, if the patient proceeds to surgical resection, the removed brain tissue can undergo molecular analysis to verify α₂A-AR pathway activation. By combining precise iEEG electrophysiological readouts with direct molecular validation, these trial designs can firmly establish the therapeutic window of α₂A-AR modulation before advancing to large-scale, chronic systemic trials 73,76.